U.S. Cancer Monoclonal Antibodies Market Size & Outlook
U.S. cancer monoclonal antibodies market, 2018-2030 (US$M)
Related Markets
U.S. cancer monoclonal antibodies market highlights
- The U.S. cancer monoclonal antibodies market generated a revenue of USD 90,642.4 million in 2023 and is expected to reach USD 183,208.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 10.6% from 2024 to 2030.
- In terms of segment, human was the largest revenue generating source in 2023.
- Humanized is the most lucrative source segment registering the fastest growth during the forecast period.
Cancer monoclonal antibodies market data book summary
| Market revenue in 2023 | USD 90,642.4 million |
| Market revenue in 2030 | USD 183,208.4 million |
| Growth rate | 10.6% (CAGR from 2023 to 2030) |
| Largest segment | Human |
| Fastest growing segment | Humanized |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Human, Humanized, Chimeric, Murine |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, GlaxoSmithKline Consumer Healthcare (GSK CH India), GlaxoSmithKline, Amgen Inc, Merck & Co Inc, Daiichi Sankyo Co Ltd, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Co, Johnson & Johnson, Bayer AG, Bristol-Myers Squibb Co, Roche Holding AG, Viatris Inc, Biogen Inc, Thermo Fisher Scientific Inc, Novo Nordisk A/S ADR, Sanofi SA, Merck KGaA |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.1% of the global cancer monoclonal antibodies market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cancer monoclonal antibodies market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 41,703.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Monoclonal Antibodies Market Scope
Cancer Monoclonal Antibodies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cancer monoclonal antibodies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer monoclonal antibodies market will help companies and investors design strategic landscapes.
Human was the largest segment with a revenue share of 52.95% in 2023. Horizon Databook has segmented the U.S. cancer monoclonal antibodies market based on human, humanized, chimeric, murine covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. cancer monoclonal antibodies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cancer monoclonal antibodies market databook
-
Our clientele includes a mix of cancer monoclonal antibodies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cancer monoclonal antibodies market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cancer monoclonal antibodies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. monoclonal antibodies market size, by source, 2018-2030 (US$M)
U.S. Cancer Monoclonal Antibodies Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
